EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

The Nephroprotective Effects of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Multicenter Saudi Arabian Study

Maha H Jamal iD, Hassan A Alzahrani iD, Duaa M Bakhshwin iD, Ranya A Ghamri iD, Fatmah S Binzomah iD, Wisam H Jamal iD, Moaz W Abulfaraj iD

Saudi Medical Journal · 2026

DOI: 10.15537/1658-3175.8778 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Saudi Medical Journal, 2026. Verfasst von Maha H Jamal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Immunoglobulin Fc Fragments. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to evaluate the effectiveness and safety of dulaglutide in individuals with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM).

Methods

This retrospective cohort study included 212 patients with CKD (stages 1–4) and T2DM treated with once-weekly dulaglutide (1.5 mg) for either 12 or 24 months at three tertiary care centers in Saudi Arabia from January 2021 to December 2023. Safety was assessed based on the presence of adverse events. Efficacy was measured using the changes in estimated glomerular filtration rate (eGFR), glycated hemoglobin (HbA1c), and body mass index (BMI). Changes in efficacy outcomes were assessed using paired t-tests.

Results

Baseline HbA1c was 9.1% (± 1.8%), BMI was 33.0 (± 6.4) kg/m2, and eGFR was 68.2 (± 28.5) mL/min/1.73 m2. At 12 and 24 months, HbA1c decreased by 1.2% (95% confidence interval [CI]: 1.0–1.4, p < 0.001) and BMI by 1.1 kg/m2 (95% CI: 0.9–1.3, p < 0.001). Further, eGFR remained stable at 12 months (change: -0.1, 95% CI: -2.2 to 2.0, p = 0.937) but increased by 2.8 mL/min/1.73 m2 (95% CI: 0.3–5.3, p = 0.029) at 24 months, particularly in stage 3 CKD (p = 0.041). By multivariable regression analysis, with adjustment for concomitant medications, dulaglutide was associated with a significant increase in eGFR increase at 24 months (adjusted mean change: 2.6 mL/min/1.73 m2, 95% CI: 0.2–5.0, p = 0.034). Patients aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsRenal Insufficiency, ChronicAdultAgedFemaleHumansMaleMiddle AgedBody Mass IndexGlomerular Filtration RateGlycated HemoglobinRetrospective StudiesSaudi ArabiaTreatment Outcome

Stichwörter der Autor:innen

Chronic kidney diseaseDulaglutideGLP-1 receptor agonistsGlomerular filtration rateType 2 diabetes mellitus

Substanzen

dulaglutideGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Ministry of Health, Saudi Arabia.
  • Department of Family Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Department of Surgery, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia.
  • Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

ORCID-Profile: Maha H Jamal, Hassan A Alzahrani, Duaa M Bakhshwin, Ranya A Ghamri, Fatmah S Binzomah, Wisam H Jamal, Moaz W Abulfaraj

Zitieren

APA

Jamal, M. H., Alzahrani, H. A., Bakhshwin, D. M., Ghamri, R. A., Binzomah, F. S., Jamal, W. H., & Abulfaraj, M. W. (2026). The Nephroprotective Effects of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Multicenter Saudi Arabian Study. Saudi Medical Journal. https://doi.org/10.15537/1658-3175.8778

Vancouver

Jamal MH, Alzahrani HA, Bakhshwin DM, Ghamri RA, Binzomah FS, Jamal WH, et al. The Nephroprotective Effects of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Multicenter Saudi Arabian Study. Saudi Medical Journal. 2026. doi:10.15537/1658-3175.8778

BibTeX
@article{Jamal2026,
  author = {Jamal, Maha H and Alzahrani, Hassan A and Bakhshwin, Duaa M and Ghamri, Ranya A and Binzomah, Fatmah S and Jamal, Wisam H and Abulfaraj, Moaz W},
  title = {The Nephroprotective Effects of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Multicenter Saudi Arabian Study},
  journal = {Saudi Medical Journal},
  year = {2026},
  doi = {10.15537/1658-3175.8778}
}
Kostenlos starten →